Tanzania Liver Cancer Therapeutics Market Report 2022 to 2030

Tanzania Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Tanzania Liver Cancer Therapeutics market will reach a value of $4.6 Mn from $1.2 Mn in 2022, growing at a CAGR of 18.5 % during 2022-2030. The Liver Cancer Therapeutics in Tanzania is dominated by a few domestic pharmaceutical companies such as Zenufa, MCL Pharmaceuticals and African Pharmaceutical. The Liver Cancer Therapeutics market in Tanzania is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Tanzania Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10TZPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Tanzania AUTHOR: Dr. Vishwa Modhia

Buy Now

Tanzania Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Tanzania Liver Cancer Therapeutics market will reach a value of $4.6 Mn from $1.2 Mn in 2022, growing at a CAGR of 18.5 % during 2022-2030.

Tanzania is a low-income, developing country in East Africa bordering the Indian Ocean. About 12% of the estimated cancers in Tanzania, were liver cancers attributed to alcohol drinking. Chronic infection with the hepatitis B or C virus, which affects between 5% and 8% of the population, is one of the leading risk factors for liver cancer in Tanzania. Liver cancer is one of the top 10 most prevalent malignancies in Tanzania, according to the Ministry of Health, Community Development, Gender, Elderly, and Children.

According to the latest WHO data published in 2020 Liver Cancer Deaths in Tanzania reached 1,413 or 0.48% of total deaths. The age-adjusted Death Rate is 5.65 per 100,000 of the population ranks Tanzania 85^th in the world. Tanzania’s government spent 3.8 % of its GDP on healthcare in 2020.

Tanzania Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

It is estimated that Africa accounts for 40% (59,900 of the 155,000 global annual cases of aflatoxin-induced liver cancer). Tanzania is implementing a regional cooperation strategy. In addition, the country is receiving international assistance in the form of concessional loans. These aspects could boost Tanzania Liver Cancer Therapeutics market.

Market Restraints

Tanzania's pharmaceutical industry confronts weak infrastructure, particularly limited storage facilities, which can influence drug quality and effectiveness. Tanzanian cancer medicine production is modest, with most drugs imported. Patients' access to and cost of these treatments is hampered because they must rely on pricey imported drugs. Tanzania has an inconsistent industrial policy and a poor business climate. These factors may deter new entrants into the Tanzania Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Zenufa Laboratories: Zenufa Laboratories is a leading pharmaceutical manufacturer in Tanzania. The company produces a range of drugs, including some used in the treatment of cancer
MCL Pharmaceuticals: MCL Pharmaceuticals is another leading pharmaceutical manufacturer in Tanzania. The company produces a range of drugs, including some used in the treatment of liver cancer
African Pharmaceutical Distributors: African Pharmaceutical Distributors is a major distributor of pharmaceutical products in Tanzania. The company supplies a range of cancer drugs, including those used in the treatment of liver cancer
Muhimbili National Hospital Pharmacy: Muhimbili National Hospital is the largest hospital in Tanzania and has a pharmacy that supplies cancer drugs, including those used in the treatment of liver cancer
Oncopha Tanzania: Oncopha Tanzania is a company that specializes in the import and distribution of cancer drugs in Tanzania. The company supplies a range of drugs used in the treatment of liver cancer

Healthcare Policies and Reimbursement Scenarios

In Tanzania, there were no clear laws or reimbursement policies for liver cancer therapies. The Tanzania Food and Drug Authority (TFDA), on the other hand, oversees the importation, distribution, and sale of all pharmaceutical products in the country, including those used to treat liver cancer. Tanzania's National Health Insurance Fund (NHIF) covers several medical treatments and operations, including cancer treatments, in terms of payment. The breadth of coverage, however, is limited, and not all liver cancer treatments may be reimbursed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.